-
Tytuł:
-
Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody.
-
Autorzy:
-
Hacohen Y; Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, UK/Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, UK/Department of Neurosciences, Great Ormond Street Hospital for Children, London, UK.
Messina S; Neurology Department, John Radcliffe Hospital, Oxford, UK.
Gan HW; Department of Paediatric Endocrinology, Great Ormond Street Hospital, London, UK.
Wright S; Department of Paediatric Neurology, Birmingham Children's Hospital, Birmingham, UK.
Chandratre S; Department of Paediatric Neurology, John Radcliffe Hospital, Oxford, UK.
Leite MI; Neurology Department, John Radcliffe Hospital, Oxford, UK/Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Fallon P; Department of Paediatric Neurology, St George's Hospital, London, UK.
Vincent A; Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.
Ciccarelli O; Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, UK.
Wassmer E; Department of Paediatric Neurology, Birmingham Children's Hospital, Birmingham, UK.
Lim M; Department of Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, King's Health Partners Academic Health Science Centre, London, UK.
Palace J; Neurology Department, John Radcliffe Hospital, Oxford, UK.
Hemingway C; Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, UK.
-
Źródło:
-
Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2018 Apr; Vol. 24 (5), pp. 679-684. Date of Electronic Publication: 2017 Aug 14.
-
Typ publikacji:
-
Journal Article; Research Support, Non-U.S. Gov't
-
Język:
-
English
-
Imprint Name(s):
-
Publication: 2006- : London : SAGE Publications
Original Publication: Houndmills, Basingstoke, Hampshire, UK : Stockton Press, c1995-
-
MeSH Terms:
-
Autoantibodies*
Immunologic Factors*
Aquaporin 4/*immunology
Endocrine System Diseases/*epidemiology
Neuromyelitis Optica/*epidemiology
Neuromyelitis Optica/*immunology
Adolescent ; Amenorrhea/epidemiology ; Amenorrhea/etiology ; Caribbean Region/epidemiology ; Child ; Cohort Studies ; Endocrine System Diseases/etiology ; Female ; Humans ; Hyperandrogenism/epidemiology ; Hyperandrogenism/etiology ; Hyperinsulinism/epidemiology ; Hyperinsulinism/etiology ; Hyponatremia/epidemiology ; Hyponatremia/etiology ; Hypothalamus/diagnostic imaging ; Hypothalamus/pathology ; Hypothyroidism/epidemiology ; Hypothyroidism/etiology ; Magnetic Resonance Imaging ; Male ; Morbidity ; Neuromyelitis Optica/complications ; Neuromyelitis Optica/diagnostic imaging ; Obesity, Morbid/epidemiology ; Obesity, Morbid/etiology ; Prevalence ; Quality of Life
-
Grant Information:
-
United Kingdom Department of Health
-
Contributed Indexing:
-
Keywords: Neuromyelitis optica (NMO); Quality of Life; endocrinopathies; hypothalamic involvement; obesity
-
Substance Nomenclature:
-
0 (Aquaporin 4)
0 (Autoantibodies)
0 (Immunologic Factors)
-
Entry Date(s):
-
Date Created: 20170815 Date Completed: 20191004 Latest Revision: 20191007
-
Update Code:
-
20240105
-
DOI:
-
10.1177/1352458517726593
-
PMID:
-
28803524
-
The involvement of the diencephalic regions in neuromyelitis optica spectrum disorder (NMOSD) may lead to endocrinopathies. In this study, we identified the following endocrinopathies in 60% (15/25) of young people with paediatric-onset aquaporin 4-Antibody (AQP4-Ab) NMOSD: morbid obesity ( n = 8), hyperinsulinaemia ( n = 5), hyperandrogenism ( n = 5), amenorrhoea ( n = 5), hyponatraemia ( n = 4), short stature ( n = 3) and central hypothyroidism ( n = 2) irrespective of hypothalamic lesions. Morbid obesity was seen in 88% (7/8) of children of Caribbean origin. As endocrinopathies were prevalent in the majority of paediatric-onset AQP4-Ab NMOSD, endocrine surveillance and in particular early aggressive weight management is required for patients with AQP4-Ab NMOSD.
